Kiniksa Reports Third-Quarter Revenue of $285.97 Million
Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $285.97 million, up 58.1% year over year. Net income was $47.35 million and diluted EPS was $0.56; growth was driven primarily by more patients receiving ARCALYST.